Forodesine in the treatment of cutaneous T-cell lymphoma

References

• Krejsgaard T, Lindahl LM, Mongan NP, et al. Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover. Semin Immunopathol. 2017;39(3):269–282.
   PubMed Web of Science ®Google Scholar
• Willemze R. Cutaneous T-cell lymphoma: epidemiology, etiology, and classification. Leuk Lymphoma. 2003;44(Suppl 3):S49–54.
   Google Scholar
• Bradford PT, Devesa SS, Anderson WF, et al. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009;113(21):5064–5073.
   PubMed Web of Science ®Google Scholar
• Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713–1722.
   PubMed Web of Science ®Google Scholar
• Trautinger F, Eder J, Assaf C, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome - update 2017. Eur J Cancer. 2017;77:57–74.
   PubMed Web of Science ®Google Scholar
• Willemze R, Hodak E, Zinzani PL, et al. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi149–154.
   PubMed Web of Science ®Google Scholar
• Dummer R, Assaf C, Bagot M, et al. Maintenance therapy in cutaneous T-cell lymphoma: who, when, what? Eur J Cancer. 2007;43(16):2321–2329.
   PubMed Web of Science ®Google Scholar
• Hosing C, Bassett R, Dabaja B, et al. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol. 2015;26(12):2490–2495.
   PubMed Web of Science ®Google Scholar
• Duarte RF, Boumendil A, Onida F, et al. Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis. J Clin Oncol. 2014;32(29):3347–3348.
   PubMed Web of Science ®Google Scholar
• Scarisbrick JJ, Prince HM, Vermeer MH, et al. Cutaneous Lymphoma International Consortium (CLIC) study of outcome in advanced stages of mycosis fungoides & Sézary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol. 2015;33(32):3766–3773.
   PubMed Web of Science ®Google Scholar
• Wright A, Wijeratne A, Hung T, et al. Prevalence and severity of pruritus and quality of life in patients with cutaneous T-cell lymphoma. J Pain Symptom Manage. 2013;45(1):114–119.
   PubMed Web of Science ®Google Scholar
• Demierre MF, Gan S, Jones J, et al. Significant impact of cutaneous T-cell lymphoma on patients’ quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey. Cancer. 2006;107(10):2504–2511.
   PubMed Web of Science ®Google Scholar
• Miles RW, Tyler PC, Furneaux RH, et al. One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase. Biochemistry. 1998;37(24):8615–8621.
   PubMed Web of Science ®Google Scholar
• Bantia S, Miller PJ, Parker CD, et al. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)–a novel potent and orally active immunosuppressive agent. Int Immunopharmacol. 2001;1(6):1199–1210.
   PubMed Web of Science ®Google Scholar
• Bantia S, Kilpatrick JM. Purine nucleoside phosphorylase inhibitors in T-cell malignancies. Curr Opin Drug Discov Devel. 2004;7(2):243–247.
   PubMedGoogle Scholar
• Korycka A, Lech-Maranda E, Robak T. Novel purine nucleoside analogues for hematological malignancies. Recent Pat Anticancer Drug Discov. 2008;3(2):123–136.
   PubMed Web of Science ®Google Scholar
• Galmarini CM, Popowycz F, Joseph B. Cytotoxic nucleoside analogues: different strategies to improve their clinical efficacy. Curr Med Chem. 2008;15(11):1072–1082.
   PubMed Web of Science ®Google Scholar
• Bantia S, Ananth SL, Parker CD, et al. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor–BCX-1777. Int Immunopharmacol. 2003;3(6):879–887.
   PubMed Web of Science ®Google Scholar
• Markert ML. Purine nucleoside phosphorylase deficiency. Immunodefic Rev. 1991;3(1):45–81.
   PubMedGoogle Scholar
• Gandhi V, Balakrishnan K. Pharmacology and mechanism of action of forodesine, a T-cell targeted agent. Semin Oncol. 2007;34(6 Suppl 5):S8–12.
   Google Scholar
• Huang M, Wang Y, Gu J, et al. Determinants of sensitivity of human T-cell leukemia CCRF-CEM cells to immucillin-H. Leuk Res. 2008;32(8):1268–1278.
   PubMed Web of Science ®Google Scholar
• Kicska GA, Long L, Horig H, et al. Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes. Proc Natl Acad Sci U S A. 2001;98(8):4593–4598.
   PubMed Web of Science ®Google Scholar
• Duvic M, Foss FM, Olsen EA, et al. Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in patients with refractory cutaneous T-cell lymphoma. Blood. 2004;104(11):abstr 2491.
   Web of Science ®Google Scholar
• Duvic M. From cell biology to therapy: forodesine. Hematology Meeting Reports. 2008;2(5):106–111.
   Google Scholar
• Duvic M, Foss FM. Mycosis fungoides: pathophysiology and emerging therapies. Semin Oncol. 2007;34(6 Suppl 5):S21–28.
   Web of Science ®Google Scholar
• Talpur R, Bassett R, Duvic M. Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sezary syndrome. Br J Dermatol. 2008;159(1):105–112.
   PubMed Web of Science ®Google Scholar
• Duvic M, Forero-Torres A, Foss FM, et al. Oral Forodesine (BCX-1777) is clinically active in refractory cutaneous T-cell lymphoma: results of a phase I/II study. Blood. 2006;108(11):abstr 2467.
   Web of Science ®Google Scholar
• Duvic M, Forero-Torres A, Foss FM, et al. Long-term treatment of CTCL with the oral PNP inhibitor, forodesine. J Clin Oncol. 2009;27(15s):abstr 8552.
   Google Scholar
• Dummer R, Duvic M, Scarisbrick J, et al. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sezary syndrome). Ann Oncol. 2014;25(9):1807–1812.
   PubMed Web of Science ®Google Scholar
• Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28(29):4485–4491.
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Kim YH, Foss F, et al. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2012;119(18):4115–4122.
   PubMed Web of Science ®Google Scholar
• Duvic M, Talpur R, Wen S, et al. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma. 2006;7(1):51–58.
   PubMedGoogle Scholar
• Dummer R, Quaglino P, Becker JC, et al. Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol. 2012;30(33):4091–4097.
   PubMed Web of Science ®Google Scholar
• Ogura M, Tsukasaki K, Nagai H, et al. Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer-cell malignancies. Cancer Sci. 2012;103(7):1290–1295.
   PubMed Web of Science ®Google Scholar
• Tsukasaki K, Tobinai K, Uchida T, et al. Phase 1/2 study of forodesine in patients with relapsed peripheral t-cell lymphoma (PTCL). J Clin Oncol. 2016;34:abstr 7542.
   Google Scholar
• Kim EJ, Hess S, Richardson SK, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest. 2005;115(4):798–812.
   PubMed Web of Science ®Google Scholar
• Banti S, Miller PJ, Parker CD, et al. Comparison of in vivo efficacy of BCX-1777 and cyclosporin in xenogeneic graft-vs.-host disease: the role of dGTP in antiproliferative action of BCX-1777. Int Immunopharmacol. 2002;2(7):913–923.
   PubMed Web of Science ®Google Scholar
• Gore L, Stelljes M, Quinones R. Forodesine treatment and post-transplant graft-versus-host disease in two patients with acute leukemia: facilitation of graft-versus-leukemia effect? Semin Oncol. 2007;34(6 Suppl 5):S35–S39.
   Google Scholar